Softwr

Healthcare · head to head

Ambra Health vs Lunit

Ambra Health logo

Ambra Health

Healthcare

Cloud medical image exchange and vendor neutral archive, now part of Intelerad

From
On request
Rated
-
Full reviewWebsite
Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Ambra Health intelerad now owns Ambra and ambrahealth.com redirects to Intelerad client support, so a buyer is committing to the Intelerad portfolio roadmap and should get written positioning on Ambra versus Intelerad own cloud PACS before signing.; Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • They diverge on capability: Ambra Health covers Image exchange, Lunit covers Lunit INSIGHT MMG.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Ambra Health and Lunit actually diverge.

Attributes where Ambra Health and Lunit differ
AttributeAmbra HealthLunit
PlatformsWeb, iOS, AndroidWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Ambra Health

  • Image exchange
  • Cloud VNA
  • Zero footprint viewer
  • Patient upload portal
  • Identity reconciliation
  • Clinical trials workflow
  • API and HL7 integration

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

What people use each for

The jobs each tool is most often brought in to do.

Ambra Health

  • A trauma centre that receives transfers from regional hospitals and needs outside CT studies readable before the patient arrives, not after a disc is walked innot Lunit
  • An oncology programme collecting outside imaging for multidisciplinary tumour board review from dozens of referring practicesnot Lunit
  • A clinical research organisation routing de identified trial imaging from many sites to one central reading facilitynot Lunit
  • A health system trying to eliminate the CD import desk by giving patients and referring practices a direct upload portalnot Lunit

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Ambra Health
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Ambra Health
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Ambra Health
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Ambra Health

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Ambra Health

  • Intelerad now owns Ambra and ambrahealth.com redirects to Intelerad client support, so a buyer is committing to the Intelerad portfolio roadmap and should get written positioning on Ambra versus Intelerad own cloud PACS before signing.
  • Ambra is built for cross organisation exchange, not for high volume in department diagnostic reading, so a radiology group that expects it to replace a departmental PACS finds the reading ergonomics and hanging protocols thinner than a dedicated PACS client.
  • Pricing scales with study volume and stored capacity, so a health system that turns on patient upload broadly sees storage grow from low value outside studies it never intended to retain, and the renewal reflects that.
  • Identity reconciliation of studies arriving with foreign patient identifiers still needs human review at volume, and sites that budget for zero touch matching end up staffing an imaging records queue.
  • Adoption depends on referring practices actually using the portal, and the vendor cannot make that happen, so image exchange projects frequently stall at the outreach and change management step rather than at the technology.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Pricing, plan by plan

Ambra Health

On request
  • Ambra Health$undefined/year
    • Priced by annual study volume and stored capacity
    • Exchange partner connections and upload portals scoped per deployment
    • Zero footprint viewer licensed with the platform

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Which should you pick?

Choose Ambra Health if

  • You need image exchange.
  • You work on Web, iOS, Android.
  • You also want cloud vna.
Ambra Health review

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Questions people ask

Is Ambra Health or Lunit better?
Neither clearly leads. Ambra Health starts at On request and Lunit at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Ambra Health or Lunit?
Ambra Health starts at On request and Lunit at On request.
Does Ambra Health or Lunit run on more platforms?
Ambra Health runs on Web, iOS, Android. Lunit runs on Web.
What is Ambra Health best used for?
Ambra Health is most often used for a trauma centre that receives transfers from regional hospitals and needs outside ct studies readable before the patient arrives, not after a disc is walked in, an oncology programme collecting outside imaging for multidisciplinary tumour board review from dozens of referring practices, a clinical research organisation routing de identified trial imaging from many sites to one central reading facility, a health system trying to eliminate the cd import desk by giving patients and referring practices a direct upload portal. Of those, a trauma centre that receives transfers from regional hospitals and needs outside ct studies readable before the patient arrives, not after a disc is walked in and an oncology programme collecting outside imaging for multidisciplinary tumour board review from dozens of referring practices are not what Lunit is typically brought in for.
What can Ambra Health do that Lunit cannot?
Ambra Health covers Image exchange, Cloud VNA, Zero footprint viewer, Patient upload portal. Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment.

Answered from the vendors’ own pages

Ambra Health: Is Ambra Health still sold under its own name?

Yes. Intelerad still markets Ambra Health as a named product line, but the standalone website redirects to Intelerad, and support and contracting run through Intelerad.

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Ambra Health: Can Ambra replace our PACS?

For image exchange, archiving and clinical viewing, yes. For high volume diagnostic radiology reading it is generally deployed alongside a departmental PACS rather than instead of one.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Ambra Health: Is pricing published?

No. It is quoted by annual study volume, stored capacity and the scope of exchange connections.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Ambra Health: Does the viewer require software on referring physician machines?

No. The viewer is zero footprint HTML5, which is the main reason referring practices adopt it at all.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Ambra Health

More on Lunit

Keep looking

Other head to heads